Mahdi Babaei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahdi Babaei has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Martin J. McKeown
University of British Columbia
2 shared publications - Sepideh Hajipour Sardouie
Pacific Parkinson’s Research Centre, University of British Columbia, Vancouver, BC V6E 2M6, Canada
2 shared publications - Hanaa Diab
Pacific Parkinson’s Research Centre, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC V6T 2B5, Canada
1 shared publication - Mahsa Naseri
Pacific Parkinson’s Research Centre, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC V6T 2B5, Canada
1 shared publication - Mahsa Naseri1 shared publication
- Martin Sheung Man Keung
Pacific Parkinson’s Research Centre, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC V6T 2B5, Canada
1 shared publication
Latest Publications
- Open Access
- 5 November 2026
- Published by IOP Publishing in Journal of Neural Engineering
Comprehensive benchmarking of EEG biomarkers for Parkinson's disease: robustness, reliability, and clinical discriminability across multiple datasets
Electroencephalography (EEG) provides a high-temporal-resolution, noninvasive window into some of the abnormalities underlying Parkinson’s disease (PD), yet reported electrophysiological biomarkers vary widely across studies due to differences in preprocessing, feature extraction, and analytical pipelines. Here we provide the first comprehensive, multi-dataset benchmarking of 16 EEG-derived biomarkers, including phase-amplitude coupling, beta burst metrics, aperiodic components, complexity measures, and beta waveform features, to evaluate their robustness, reliability, and clinical discriminability. Using three independent resting-state EEG datasets, with two preprocessing conditions evaluated for one dataset, we assessed the effects of preprocessing, window length, within-session variability, channel aggregation strategies, and clinical group differences (healthy controls vs. PD OFF-medication, healthy controls vs. PD ON-medication, and PD OFF- vs. ON-medication). Cross-dataset reproducibility of group-level effects was additionally evaluated using effect-size pattern similarity, biomarker rank concordance, effect-direction consistency, and random-effects meta-analysis. Aperiodic features, entropy and complexity measures, and fractal metrics demonstrated high methodological robustness across preprocessing methods, window lengths, and aggregation strategies, and several showed disease- and medication-related effects across datasets, although effect magnitude and statistical significance varied across datasets and analytical conditions. In contrast, oscillatory biomarkers, including beta-gamma phase-amplitude coupling, burst-derived metrics, and waveform-asymmetry features, showed substantial variability across methodological choices and lower within-session consistency. However, this methodological sensitivity should not necessarily be interpreted as lower biological relevance, as these measures may capture more transient or state-dependent physiological dynamics. Fully-denoised data improved group-level separability, for several biomarkers in Dataset 1. Together, these findings identify several biomarkers with comparatively strong methodological robustness for further biological and clinical validation and highlight methodological factors that contribute to inconsistencies in the PD literature. This benchmarking framework provides practical guidance for standardizing biomarker analysis while emphasizing that methodological robustness, biological sensitivity, and clinical utility represent distinct dimensions of biomarker performance.
- 5 November 2026
- Published by IOP Publishing in Journal of Neural Engineering
Open AccessComprehensive benchmarking of EEG biomarkers for Parkinson's disease: robustness, reliability, and clinical discriminability across multiple datasets
Electroencephalography (EEG) provides a high-temporal-resolution, noninvasive window into some of the abnormalities underlying Parkinson’s disease (PD), yet reported electrophysiological biomarkers vary widely across studies due to differences in preprocessing, feature extraction, and analytical pipelines. Here we provide the first comprehensive, multi-dataset benchmarking of 16 EEG-derived biomarkers, including phase-amplitude coupling, beta burst metrics, aperiodic components, complexity measures, and beta waveform features, to evaluate their robustness, reliability, and clinical discriminability. Using three independent resting-state EEG datasets, with two preprocessing conditions evaluated for one dataset, we assessed the effects of preprocessing, window length, within-session variability, channel aggregation strategies, and clinical group differences (healthy controls vs. PD OFF-medication, healthy controls vs. PD ON-medication, and PD OFF- vs. ON-medication). Cross-dataset reproducibility of group-level effects was additionally evaluated using effect-size pattern similarity, biomarker rank concordance, effect-direction consistency, and random-effects meta-analysis. Aperiodic features, entropy and complexity measures, and fractal metrics demonstrated high methodological robustness across preprocessing methods, window lengths, and aggregation strategies, and several showed disease- and medication-related effects across datasets, although effect magnitude and statistical significance varied across datasets and analytical conditions. In contrast, oscillatory biomarkers, including beta-gamma phase-amplitude coupling, burst-derived metrics, and waveform-asymmetry features, showed substantial variability across methodological choices and lower within-session consistency. However, this methodological sensitivity should not necessarily be interpreted as lower biological relevance, as these measures may capture more transient or state-dependent physiological dynamics. Fully-denoised data improved group-level separability, for several biomarkers in Dataset 1. Together, these findings identify several biomarkers with comparatively strong methodological robustness for further biological and clinical validation and highlight methodological factors that contribute to inconsistencies in the PD literature. This benchmarking framework provides practical guidance for standardizing biomarker analysis while emphasizing that methodological robustness, biological sensitivity, and clinical utility represent distinct dimensions of biomarker performance.
- Open Access
- 3 February 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (2) , 352
Rapid Profiling of EEG Responses to Non-Invasive Brain Stimulation in Parkinson’s Disease: A Biomarker-Driven Screening Framework
Background/Objectives: Parkinson’s disease (PD) is associated with alterations in resting-state Electroencephalogram (EEG) biomarkers. Identifying stimulation protocols that reliably shift these biomarkers toward healthy-like patterns is essential for developing personalized neuromodulation strategies. This study introduces a rapid, biomarker-driven framework for screening the EEG effects of diverse Galvanic Vestibular Stimulation (GVS) waveforms in PD. Methods: More than 300 subthreshold GVS stimuli were delivered during resting-state EEG to PD (n = 5) subjects and Healthy Controls (n = 5). A composite biomarker score that included spectral, cross-frequency, aperiodic, and complexity measures quantified stimulation-related changes. A linear classifier and multi-criteria decision analysis were used to evaluate and rank stimuli. Results: Stimulation produced consistent improvements in the composite biomarker score, with the strongest effects observed for beta-range sinusoids, multisine waveforms, frequency-modulated stimuli with a 75 Hz carrier, and PAC-modulated signals. No significant post-stimulation carryover effects were detected. Conclusions: While preliminary, this exploratory framework enables rapid, interpretable profiling of EEG responses to non-invasive stimulation in PD. By prioritizing candidate GVS protocols based on biomarker shifts rather than behavioural endpoints, the approach provides a practical foundation for future personalized neuromodulation strategies.
- 3 February 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (2) , 352
Open AccessRapid Profiling of EEG Responses to Non-Invasive Brain Stimulation in Parkinson’s Disease: A Biomarker-Driven Screening Framework
Background/Objectives: Parkinson’s disease (PD) is associated with alterations in resting-state Electroencephalogram (EEG) biomarkers. Identifying stimulation protocols that reliably shift these biomarkers toward healthy-like patterns is essential for developing personalized neuromodulation strategies. This study introduces a rapid, biomarker-driven framework for screening the EEG effects of diverse Galvanic Vestibular Stimulation (GVS) waveforms in PD. Methods: More than 300 subthreshold GVS stimuli were delivered during resting-state EEG to PD (n = 5) subjects and Healthy Controls (n = 5). A composite biomarker score that included spectral, cross-frequency, aperiodic, and complexity measures quantified stimulation-related changes. A linear classifier and multi-criteria decision analysis were used to evaluate and rank stimuli. Results: Stimulation produced consistent improvements in the composite biomarker score, with the strongest effects observed for beta-range sinusoids, multisine waveforms, frequency-modulated stimuli with a 75 Hz carrier, and PAC-modulated signals. No significant post-stimulation carryover effects were detected. Conclusions: While preliminary, this exploratory framework enables rapid, interpretable profiling of EEG responses to non-invasive stimulation in PD. By prioritizing candidate GVS protocols based on biomarker shifts rather than behavioural endpoints, the approach provides a practical foundation for future personalized neuromodulation strategies.